रोमेनियन में NÓXĂ का क्या अर्थ होता है?
ध्यान दें: परिभाषा का रोमेनियनमें स्वचालित अनुवाद किया गया है। रोमेनियन में «nóxă» की
मूल परिभाषा देखने के लिए क्लिक करें।
हिन्दी में परिभाषा का
स्वचालित अनुवाद देखने के लिए क्लिक करें।
रोमेनियनशब्दकोश में nóxă की परिभाषा
NOXA च। एक एजेंट या शरीर पर हानिकारक कार्रवाई के साथ एक कारक जो वातावरण में फैलता है, विशेष रूप से विभिन्न तकनीकी प्रक्रियाओं के दौरान। NÓXĂ ~e f. Agent sau factor cu acțiune dăunătoare asupra organismului care se răspândește în atmosferă mai ales în timpul diferitelor procese tehnologice.
ध्यान दें: परिभाषा का रोमेनियनमें स्वचालित अनुवाद किया गया है। रोमेनियन में «nóxă» की
मूल परिभाषा देखने के लिए क्लिक करें।
हिन्दी में परिभाषा का
स्वचालित अनुवाद देखने के लिए क्लिक करें।
रोमेनियन किताबें जो «NÓXĂ» से संबंधित हैं
निम्नलिखित ग्रंथसूची चयनों में
nóxă का उपयोग पता करें।
nóxă aसे संबंधित किताबें और रोमेनियन साहित्य में उसके उपयोग का संदर्भ प्रदान करने वाले उनके संक्षिप्त सार।.
1
Trends in Stem Cell Proliferation and Cancer Research - Pagina 223
Noxa is the first BH3-only protein reported to be a p53 target. It was cloned using a differential display technique and called Noxa, the Latin word for “damage” (Oda et al. 2000). Together with Puma, Noxa accounts for all of the proapoptotic ...
Rodrigo R. Resende, Henning Ulrich, 2013
2
25 Years of P53 Research - Pagina 167
However, with knock-out mice for PUMA, Noxa and Bax now available, it became clear that none of them has the power to phenocopy p53-/- mice (Jeffers et al. 2003; Nakano et al. 2001; Shibue et al. 2003; Villunger et al. 2003). Instead, each ...
Pierre Hainaut, Klas G. Wiman, 2007
3
Cell Apoptosis Research Trends - Pagina 220
A number of genes encoding these proteins, such as BAX, NOXA, HRK, PUMA, and SIVA, contain p53 response elements, and their regulation has been shown to depend on p53 activity [29, 30, 74-76]. On the other hand, it has also been ...
4
Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy
P ERK P P P P P CREB P Puma P Effects of Raf/MEK/ERK, PI3K/Akt, JNK and p53 Pathways on Noxa and Puma and the Induction of Apoptosis Foxo3A Bak Bak Apoptosis Bim Mcl-1 Mdm-2 p53 Puma Figure 7.4. Effects of Raf/MEK/ERK and ...
5
An Introduction to the Study of Justinian's Digest: ... - Pagina 134
14) noxa is used of mere 'harm', e.g. sine ullius noxa urbis exercitus reductus. Ovid has noxa 'harm' in Fast. vi. 130; Met. xv. 334; 'fault' in Met. I. 214; Pont. II. 9. 71. Manilius has noxia in the sense of 'guilt' II. 602 ; IV. 94 ; 418 ; noxa as ' harm ' II.
6
A Censure and Examination of Mr. Thomas Ruddiman's ... - Pagina 199
Æneid. 1. 45. stating the difference between noxa and noxia, that noxla is the fault or transgression, and noxa the punishment : he ought to have added, that Fronto says the direct contrary, viz. th3t noxa signifies the fault or offence, and noxia ...
7
Histone Deacetylase Inhibitors as Cancer Therapeutics - Pagina 180
A number of studies have reported the upregulation of Noxa and/or Puma in cell lines following treatment with a number of structurally diverse HDACi (Inoue et al., 2007; Shankar et al., 2005; Singh et al., 2005; XargayTorrent et al., 2011). 10.1.
Interestingly, loss of either PUMA or NOXA alone offered less protection from DNA damage-induced apoptosis than p53 deficiency, suggesting a degree of functional redundancy within the two BH3-only proteins (Villunger et al., 2003). Indeed ...
Gerry Melino, David Vaux, 2010
9
Diss. inaug. ... de noxa pharmacophilias, von dem Schaden ... - Pagina 3
Johann Juncker, Carl S. Jaenisch. PROOEMIVM; * atio abuiùum, quicommittuHtur circa medica m en ta, vel in Medico, vel in Phar- macopola, vel deniquein ipfo aegrotante quaerenda eft. Quiiibet diuerfo modo abuti poteft medicamentis; ...
Johann Juncker, Carl S. Jaenisch, 1755
10
Oxidants and Antioxidant Defense Systems - Volumul 2 - Pagina 21
A type I noxa is taken up actively or passively into the body (extracellular space and/or cells) where it generates ROS or induces the generation of ROS. The site of ROS generation is the extracellular space or the cell lumen. Type II noxae ...
